The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial

Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with an estimated prevalence of about 1/3000, independent of ethnicity, race, or gender. Attention Deficit Hyperactivity like Disorder (ADHD)-like characteristics are often reported in patients with NF1. We hypothesised that learning d...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Orphanet journal of rare diseases 2014-09, Vol.9 (1), p.142, Article 142
Hauptverfasser:	Lion-François, Laurence, Gueyffier, François, Mercier, Catherine, Gérard, Daniel, Herbillon, Vania, Kemlin, Isabelle, Rodriguez, Diana, Ginhoux, Tiphanie, Peyric, Emeline, Coutinho, Virginie, Bréant, Valentine, des Portes, Vincent, Pinson, Stéphane, Combemale, Patrick, Kassaï, Behrouz
Format:	Artikel
Sprache:	eng
Schlagworte:	Anxiety Attention deficit hyperactivity disorder Behavior Child Child & adolescent psychiatry Children & youth Clinical trials Cross-Over Studies Dose-Response Relationship, Drug Double-Blind Method Drug therapy Female Follow-Up Studies Humans Hyperactivity Impulsivity Inventory Learning disabled Life Sciences Male Medical research Medication Medicine, Experimental Methylphenidate Methylphenidate - therapeutic use Methylphenidate hydrochloride Neurobiology Neurofibromatosis Neurofibromatosis 1 - diagnosis Neurofibromatosis 1 - drug therapy Neurofibromatosis 1 - psychology Neurons and Cognition Patient outcomes Pediatrics Pharmaceutical sciences Rare diseases Statistical analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!